Sanofi SA PARYŻ Euronext: SAN NYSE: SNY p. farmaceutyczny

[slayer74]

Sanofi (NASDAQ:SNY) stock fell 1.4% despite the French healthcare group raising its peak sales target for eczema-treatment product Dupixent, suffering from its lack of a COVID-19 vaccine.

[slayer74]

Sanofi (PA:SASY) stock rose 0.8% after the French pharmaceutical giant said it expects to list its drug ingredients business in May, having received approval from the French stock market regulator.

[slayer74]

Sanofi's (EPA:SASY) first quarter earnings gained over 16% on continued sales growth of its bestselling drug Dupixent

[slayer74]

Sanofi (NASDAQ:SNY) stock fell 0.8% despite the French drugmaker saying the COVID-19 vaccine candidate it has developed jointly with GSK (LON:GSK) in two trials showed a potential to protect against the virus's main variants of concern when used as a booster jab.

[slayer74]

Sanofi SA (EPA:SASY) also jumped after the French drugmaker said its COVID-19 vaccine candidate delivered 72% efficacy in adults against the Omicron strain, citing data gathered in a study.

[slayer74]

Reuters) -French healthcare group Sanofi (NASDAQ:SNY) lifted its full-year earnings outlook on continued forecast-beating sales growth for its bestselling drug Dupixent.

In a statement on Thursday, Sanofi said it now expects 2022 adjusted earnings per share to grow by about 15%, excluding the effect of currency swings. It had previously predicted low double-digit percentage growth.

Sanofi's second-quarter business operating income, or adjusted earnings before interest and tax, rose 21.5% to 2.75 billion euros ($2.81 billion), surpassing the average analyst estimate of 2.66 billion euros posted on the company's website.

In March the French group said peak annual sales of Dupixent, jointly developed with Regeneron (NASDAQ:REGN), would be more than 13 billion euros, up from a previous target of more than 10 billion euros.

Revenue from anti-inflammatory treatment Dupixent jumped 43.4% to 1.96 billion euros in the reported quarter, beating an analyst consensus of 1.86 billion euros, on prescriptions in dermatitis, asthma and certain nasal infections.

The company's consumer healthcare unit, a maker of over-the-counter drugs (OTC), lifted sales by 9.1% to 1.27 billion euros, driven by revenue in Europe and Latin America and as customers stocked up on cough an cold remedies during an upswing in COVID-19 infections.

Finance chief Jean-Baptiste de Chatillon told reporters the business, which includes parts acquired from Boehringer Ingelheim, was making further progress under a 2019 plan to become a standalone business.

But the CFO said there were no conclusions to be drawn from the separate listing this month and underwhelming market value of OTC group Haleon, previously owned by GSK and Pfizer (NYSE:PFE).

He added that Sanofi and development partner GSK were still waiting to hear back from regulators on their protein-based COVID-19 vaccine candidate, modelled on the Beta variant.

The partners set out to help to fight the pandemic but they do not see it as a major economic opportunity, he said. "That has not changed from the beginning," he adde

[slayer74]

(Reuters) -Sanofi stopped further work on amcenestrant, once seen to have large potential against breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.

The move weighed on shares and put more pressure on Sanofi (NASDAQ:SNY) to bolster its pipeline of drug candidates as it becomes increasingly dependent on its multi-billion best seller, fast-growing exzecma and asthma treatment Dupixent.

Sanofi has also fallen far behind in the race to develop COVID-19 vaccines.

A trial dubbed AMEERA-5, which was testing amcenestrant on women with newly-diagnosed advanced breast cancer, was stopped early because an independent monitoring panel found no signs of it working."All other studies of amcenestrant, including in early-stage breast cancer (AMEERA-6), will be discontinued," Sanofi said.

The shares dropped 4.9% at 0855 GMT, the biggest loss on the French blue chip index CAC40

Separately, the plaintiff in the first lawsuit over the heartburn drug Zantac, which has also been weighing on the French company's shares recently, on Tuesday agreed to drop his case.

Sanofi was among a range of companies selling Zantac, which U.S. regulators pulled from the market in 2020.

Since the investor scare over Zantac, which started a week ago, Sanofi shares have dropped more than 13% to a 10-month low, based on closing prices.

In March, Sanofi's shares were hit when the company announced disappointing amcenestrant results of a breast cancer study involving previously treated women.

The company has previously said the drug candidate's biggest commercial opportunity was as a treatment early after diagnosis.

"This was a flagship drug in pipeline and important oncology asset," wrote Credit Suisse analyst Jo Walton.

Sanofi said the drug, which was used in combination with Pfizer (NYSE:PFE)'s established Ibrance in the study, "did not meet the prespecified boundary for continuation," when compared to a group of patients in the trial on standard hormone therapy.

Amcenestrant belongs to a class of pills known as selective oestrogen receptor degraders (SERD) to fight tumours that grow in response to oestrogen, which are estimated to account for up to 80% of all breast cancer cases.

The market opportunity for oral SERDs has attracted a range of drugmakers including Roche and AstraZeneca (NASDAQ:AZN), who are working on pills known as giredestrant and camizestrant, respectively.

The drugs are designed to work like AstraZeneca's established injectable breast cancer drug Faslodex, while offering a less burdensome route of administration.

Roche and AstraZeneca did not immediately respond to a request for comment.

Another oral SERD, U.S. biotech firm Radius Health (NASDAQ:RDUS) Inc’s elacestrant, in which Italy’s unlisted Menarini Group owns rights, has seen better fortunes with a priority review status given by U.S. regulators last week.

Radius Health shares soared in October 2021 on positive elacestrant trial results

[slayer74]

(Reuters) -Sanofi said on Thursday it won European Union approval for its COVID-19 vaccine booster, jointly made with British partner GSK, after a drawn-out development effort that saw the pair fall behind now-dominant vaccine suppliers.

[slayer74]

Sanofi (EPA:SASY) stock rose 1.1% after the French health group dropped its bid for biotech company Horizon Therapeutics (NASDAQ:HZNP), potentially leaving the way open for Amgen (NASDAQ:AMGN) to launch a bid.

[slayer74]

#Sanofi will pay a €3.56 (+6.9%) per share dividend in 2023. Biggest dividend hike in more than a decade for the @dividendaristo pharmaceuticals giant. #France

[slayer74]

Sanofi hones in on type 1 diabetes in $2.9 billion Provention Bio deal

(Reuters) -France's Sanofi (NASDAQ:SNY) SA on Monday agreed to acquire Provention Bio Inc for $2.9 billion to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks.

The deal builds on an existing co-promotion agreement between the two companies, and would give the French drugmaker full ownership of the drug, Tzield, Sanofi said, adding it expects to complete the acquisition in the second quarter of 2023.

While growth in asthma and eczema drug Dupixent is boosting Sanofi's sales, investors have criticised its drug development pipeline as weak.

Provention Bio's shares nearly quadrupled in premarket trade from their last close at $6.70 after Sanofi agreed to buy the company at $25 per share in cash.

"The speed of the acquisition, combined with the large premium, suggests a competitive process, whereby Sanofi may have needed to respond to an unsolicited bid from another pharma (company)," SMBC Nikko Securities America analyst David Hoang said in an email.

Shares of Sanofi were down 1.5% in afternoon trade in Paris.

Sanofi, the maker of long acting insulin products Toujeo and Lantus for type 2 diabetes, in 2019 quit further type 2 diabetes drug development.

Chief Executive Officer Paul Hudson said last month the company saw great promise in type 1 diabetes drug development and reaffirmed his commitment to steer clear of further work on type 2 diabetes and obesity.

U.S.-based biotech firm Provention Bio won approval in the United States last year for Tzield, making it the first drug indicated to delay the onset of the third and final stage of type 1 diabetes in adults and children aged 8 years and older at stage 2.

https://www.investing.com/news/economy/ ... al-3028549

[slayer74]

Sanofi (EPA:SASY) stock rose 0.4% after the drugmaker said it would slash U.S. list prices for its most-prescribed insulin product, Lantus, next year following similar moves by U.S. rivals.